49 results about "Hydrocortisone" patented technology

The present invention discloses a complete medium for culturing DF-1 cells, including DMEM basal medium 13.7g / L, insulin, non-essential amino acids, transferrin, glutathione, ascorbyl phosphate, sodium selenite, ethanolamine, hydrocortisone, and newborn calf serum. Wherein non-essential amino acids include glycine, alanine, proline, serine, and asparagine. A complete medium for culturing DF-1 cells provided by the present invention can well promote the proliferation of DF-1 cells, can achieve the same proliferation effect as high-concentration fetal bovine serum, and is suitable for the adherent culture of DF-1 cells; using low-concentration newborn calf serum, it is possible to greatly avoid the batch differences, unstable culture results, cytotoxicity, and high risk of carrying pathogens brought by the culture medium with high-concentration serum, narrow application range, expensive fetal bovine serum, and high culture cost; the components are simple, the culture medium preparation process is short in time consumption, the culture efficiency is high, the repeatability is good, and it is suitable for batch production.

Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.

The invention provides a 3-hydroxypyrone derivative as well as a preparation method and application thereof, the compound can effectively inhibit release of proinflammatory cytokines in lipopolysaccharide-induced microglial cells, inhibit release of NO by the lipopolysaccharide-induced microglial cells, inhibit apoptosis of polysaccharide-induced microglial cells, and inhibit apoptosis of lipopolysaccharide-induced microglial cells. The compound has excellent anti-neuroinflammation activity and neuroprotective effect, the activity of the compound is superior to that of positive controls such as curcumin and hydrocortisone, and the compound can be used for preventing and / or treating neuroinflammation and neurodegenerative diseases.

The invention discloses application of phosphatidylserine-hydrocortisone microvesicles in preparation of a medicine for treating microvascular regeneration after cerebral apoplexy, and relates to the technical field of biomedicine. According to the microbubble, the blood brain barrier can be accurately opened through the ultrasonic vacuolation technology, the medicine can be delivered in a targeted mode, nerve protection and function improvement are accurately evaluated through ultrasonic super-resolution micro blood flow imaging, and microvessel regeneration is accurately regulated and controlled based on H3K18 lactic acid modification.

The application relates to the technical field of animal model construction, in particular to a construction method and application of a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model. The construction method comprises the following steps: a model group animal is subjected to modeling by adopting the method of senna leaf water decoction gavage and hydrocortisone and cyclophosphamide injection, and a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model is obtained. In the application, the three of senna leaf, hydrocortisone and cyclophosphamide are used in synergy to administer the animal model, and the complex syndrome of the clinical spleen-kidney yang deficiency type DOR is accurately reproduced, and modern scientific basis is provided for the theories of traditional Chinese medicine such as the same treatment for different diseases.

The invention relates to a culture method and a culture medium for reducing the number of differential transcripts of epithelial organoid and in-vivo tissues, and solves the technical problems of low growth rate and low formation rate of the organoid in the prior art. The basic components of the culture medium comprise a DMEM / F12 basal culture medium, a penicillin-streptomycin solution, a Glutamax additive, a recombinant spinal protein, a recombinant head protein, Y-27632, an epidermal growth factor, an N-2-hydroxyethyl piperazine-N-2-ethanesulfonic acid buffer solution, nicotinamide, A83-01 and CHIR99021, and the additional components of the culture medium comprise a Wnt-3A additive, an ITS-X additive and hydrocortisone. The invention also provides a culture method of the epithelial organoid. The method can be used for culturing epithelial organs.

An intranasal composition generally includes hydrocortisone, a hydrocortisone derivative, or a salt thereof. A method of administering an intranasal composition that includes hydrocortisone, a hydrocortisone derivative, or a salt thereof to a subject. A method of treating adrenal insufficiency in a subject, the method includes administering to a subject, a dose of a composition comprising hydrocortisone, a hydrocortisone derivative, or a salt thereof in an amount effective to treat adrenal insufficiency.

The present invention relates to an epithelial organoid culture medium and a culture method, which solve the technical problems of low growth rate and low formation rate of organoids in the prior art. The epithelial organoid culture medium contains basic components and additional components. The basic components include DMEM / F12 basal medium, penicillin-streptomycin solution, Glutamax additive, recombinant spondin, recombinant norrin, Y-27632, epidermal growth factor, N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer solution, nicotinamide, A83-01 and CHIR99021. The additional components include Wnt-3A, ITS-X additive and hydrocortisone. The present invention also provides a culture method for epithelial organoids. The present invention can be used for the culture of epithelial organoids.

The present invention belongs to the technical field of biomedicine, and specifically relates to a nociceptor skin organoid chip and its culture medium, construction method and application. A culture medium for a nociceptor skin organoid chip, the culture medium is composed of fetal bovine serum and the following components added to the fetal bovine serum: epidermal growth factor, bovine pituitary extract, Normocin, B27, nerve growth factor, insulin, hydrocortisone, human brain-derived neurotrophic factor and capsaicin. Using this culture medium to co-culture a skin chip with nociceptors to obtain a nociceptor skin organoid chip, which can be used for the verification of pain perception effects.

Orodispersible film (ODF) is an innovative drug formulation that allows for adjustable dosing and improved patient compliance. It is administered into the mouth where it dissolves, making it suitable for children. The present invention provides an optimized ODF gel formulation and an optimal ODF containing therapeutic doses of hydrocortisone-type corticosteroids (HTC). This ODF is thin, flexible and transparent, and suitable for production in hospital pharmacy using standard equipment. The ODF of the invention allows accurate hydrocortisone levels to be released systemically in patients in need thereof, and its good physico-chemical stability is herein demonstrated for several months. This opens up new opportunities for use in pediatric patients, notably for children suffering from congenital adrenal hyperplasia.

A method of preparing a mouse model of herpes using a herpes simplex virus and hydrocortisone, and a mouse model of herpes prepared using the method are disclosed. The method makes it possible to obtain an animal model in which symptoms of herpes clearly appear. The obtained animal model can be widely used in the development of therapeutic agents for herpes simplex virus infection. A use of the mouse model in screening and developing a candidate therapeutic agent is also disclosed.

The invention belongs to the technical field of chemical medicines, and particularly relates to a prednisolone hemisuccinate impurity control method, which comprises the following steps: by taking prednisolone acetate as an initial raw material, condensing, reducing, hydrolyzing and refining to obtain prednisolone. The method comprises the following steps: dissolving refined prednisolone in a succinic anhydride, pyridine and ethyl acetate system, carrying out an esterification reaction to obtain a prednisolone hemisuccinate crude product, dissolving the prednisolone hemisuccinate crude product in an organic solvent, carrying out reflux decoloration, carrying out rotary evaporation to remove the organic solvent, carrying out elutriation, filtering, and drying to obtain a prednisolone hemisuccinate refined product. According to the invention, the variety and content of 11-epihydrocortisone, prednisone, hydrocortisone and other key impurities doped in prednisolone hemisuccinate can be effectively controlled, so that the content of the obtained product is greater than 99%, the weight loss on drying is less than or equal to five thousandths, the content of all impurities is controlled to be less than 2.5 thousandths, and the purity of the prednisolone hemisuccinate is greatly improved. And a powerful quality guarantee is provided for competition of the product in the international market.

This invention relates to a method for constructing and evaluating an animal model of Alzheimer's disease characterized by deficiency and blood stasis. Based on APP / PS1 mice, the model was induced by sleep deprivation, hydrocortisone, and carrageenan to induce qi deficiency, kidney deficiency, and blood stasis, respectively, for a total modeling period of 28 days, resulting in an animal model of Alzheimer's disease with deficiency and blood stasis. This model was constructed using a multi-factor combined approach, and its symptom manifestations are consistent with clinical observations. It is simple, effective, and easy to operate, providing a reliable experimental vehicle for the development of innovative drugs and the study of mechanisms of action in Alzheimer's disease with deficiency and blood stasis.

The present application relates to a culture method and culture medium for reducing the number of epithelial organoids and in vivo tissue differential transcripts, which solves the technical problems of low growth rate and low formation rate of organoids in the prior art. The epithelial organoid culture medium contains basic components and additional components. The basic components contain DMEM / F12 basic medium, penicillin-streptomycin solution, Glutamax additive, recombinant vertebral protein, recombinant cephalopod protein, Y-27632, epidermal growth factor, N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer solution, nicotinamide, A83-01 and CHIR99021. The additional components contain Wnt-3A, ITS-X additive and hydrocortisone. The present application simultaneously provides a culture method for epithelial organoids. The present application can be used for the culture of epithelial organoids.

Provided herein are oral liquid formulations of hydrocortisone. Also provided herein are methods of making and using hydrocortisone oral liquid compositions for the treatment of certain diseases including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, and others.

The present invention discloses a carbonyl reductase mutant and its application in synthesizing 11β-hydroxysteroid compounds. Carbonyl reductase derived from Homo sapiens is modified by semi-rational design methods to provide a carbonyl reductase mutant. The mutant can efficiently catalyze the synthesis of 11β-hydroxysteroid compounds prednisolone, hydrocortisone and methylprednisolone using prednisone, cortisone and methylprednisolone as substrates.

This disclosure provides fast acting itch relief and cooling sprays containing hydrocortisone, a cooling agent, such as sensate molecule (e.g. menthyl lactate), and a soothing agent (such as e.g., Aloe vera). The sprays of the disclosure can be used to relieve itching associated with minor skin irritations, inflammation, and rashes due to eczema, psoriasis, poison ivy, oak, sumac, insect bites, detergents, jewelry, cosmetics, soaps, seborrheic dermatitis. The disclosure also provides for methods of treating skin with cooling sprays as well as containers containing the spray.

The invention relates to the technical field of external ointment, in particular to compound external ointment for treating leukoplakia vulvae and a preparation method of the compound external ointment. 0.03 part of tacrolimus; 2.5 parts of hypocrellin; 5 parts of a cortex phellodendri extract; 10 parts of hyaluronic acid; 3 parts of vitamin E; and 70-75 parts of a matrix. Inflammation is rapidly controlled through low-efficiency glucocorticoid, local immune abnormality is inhibited through the immunomodulator, tissue is repaired through traditional Chinese medicine components, and bacteria are resisted, so that a quick-acting and long-acting combined mode is formed, hormone side effects are neutralized by adding hyaluronic acid and vitamin E, and the feasibility of the treatment course is prolonged; the total effective rate of the combined medicine for avoiding vitamin E oxidation through low-temperature mixing is remarkably higher than that of a traditional scheme, the occurrence rate of skin atrophy is reduced to 4% and far lower than 22% of that of the traditional scheme, and meanwhile, the staged mixing process ensures that the retention rate of active ingredients is larger than 95% and is remarkably superior to that of the traditional process.

The invention discloses a hydrocortisone compound ointment preparation for treating haemorrhoids, and belongs to the technical field of medicines. The technical problem to be solved is to provide a hydrocortisone compound ointment preparation which has a good hemorrhoid treatment effect and is stable. The hydrocortisone compound ointment preparation comprises the following components in percentage by weight: 0.15%-1% of corticoid, 0.025%-0.1% of a vasoconstrictor, 2%-4% of a local anesthetic, 0.1%-1.5% of L-menthol, 0.02%-0.5% of chlorhexidine acetate and 0.05%-1% of allantoin. The hydrocortisone compound ointment preparation disclosed by the invention has the medicinal effects of relieving pain and discomfort of patients suffering from haemorrhoids, promoting healing and repairing of haemorrhoids tissues, preventing infection and relieving inflammatory response, and has obvious effects of stopping bleeding and relieving swelling and pain in haemorrhoids treatment.

The invention relates to the technical field of biology, in particular to a dissociation agent and a kit for progesterone determination. According to the invention, the sample dissociation agent for progesterone detection is obtained through optimized screening, and the sample dissociation agent comprises hydrocortisone, prednisolone and mono (2-ethylhexyl) phthalate (MEHP); when the dissociation agent components act independently or in a combined mode, the sensitivity to sample detection is high, the detection linear range is good, the dissociation agent is well related to a comparison reagent, the dissociation effect is improved remarkably on the whole, progesterone can be better released from corticosteroid binding protein, albumin and sex hormone binding globulin, and the progesterone dissociation agent is suitable for being used for detecting progesterone. The combination of progesterone and a captured antibody is facilitated, and the sensitivity and the accuracy can be effectively improved. Moreover, the reagent can be directly added into reagent components, so that the dissociation process and the immune reaction are carried out at the same time, the immune reaction is simple and efficient, and the reaction efficiency is improved.

The invention discloses a hydrocortisone butyrate cream and a preparation method thereof. Each gram of the hydrocortisone butyrate cream comprises the following components: 1 mg of hydrocortisone butyrate, 100-120 mg of an oil phase solid, 100-150 mg of white vaseline, 40-60 mg of light liquid paraffin, 30-40 mg of an emulsifier, 5-20 mg of salicylic acid, 10-40 mg of lecithin, 50-80 mg of a humectant, 1-2 mg of anhydrous sodium citrate, and the balance of water. On the basis of the existing prescription, the salicylic acid and the lecithin are added into the formula, and the dosages of the salicylic acid, the lecithin and other auxiliary materials are controlled, so that the hydrocortisone butyrate cream which is small in generation amount of degraded impurities and relatively good in stability is obtained.

The invention discloses a pharmaceutical composition for chronic scytitis, and belongs to the technical field of pharmaceutical compositions. The pharmaceutical composition for scytitis comprises an ethanol solution of a tripterygium wilfordii extract with the concentration of 15 mg / mL and a hydrocortisone solution with the mass percentage content of 1%. The combination of the tripterygium wilfordii extract and the hydrocortisone in the pharmaceutical composition for skin inflammation has a good synergistic anti-inflammatory effect, and side effects of the hydrocortisone are reduced.

The present disclosure relates generally to the treatment of adrenal dysfunction (such as congenital adrenal hyperplasia) with a combination of 2‑thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl (crinecerfont) and certain pharmaceutical compositions of hydrocortisone (such as a delayed release oral pharmaceutical composition of hydrocortisone).

The present application relates to the technical field of gout treatment, and more specifically, it relates to a serrata huperzine derivative, a preparation method thereof, and its application in anti-gout drugs. In the first aspect, the present application discloses a serrata huperzine derivative compound having the general formula (I) below; in the second aspect, the present application discloses a preparation method of the above-mentioned serrata huperzine derivative; in the third aspect, the serrata huperzine derivative of the present application can be used in gouty arthritis, and such serrata huperzine derivatives represented by 3k and 3q significantly inhibit the release of IL-1β induced by sodium urate at a concentration of 30 μM. Compared with the clinical anti-inflammatory drugs hydrocortisone, indomethacin, and colchicine, the serrata huperzine derivatives of the present application have a good balance between high inhibitory activity and low cytotoxicity, and have good application prospects. #imgabs0#

The invention relates to the technical field of microorganisms, in particular to lactobacillus kefir and application thereof in the aspect of regulating animal immune functions. The invention provides Kefir lactobacillus brachyphyllum Fanghua, and the preservation number of the Kefir lactobacillus brachyphyllum Fanghua is CGMCC (China General Microbiological Culture Collection Center) NO.27733 Research finds that compared with an immunosuppression model mouse constructed by using hydrocortisone, the weight of immune organs thymus and spleen can be increased, the number of peripheral blood leucocytes can be increased, and immune cell composition and expression of inflammation-related genes can be changed when the mouse is fed with the Lactobacillus kefir Fanghua. Besides, after the excrement of the aged mice fed with the lactobacillus kefir Fanghua is transplanted to the sterile mice, compared with excrement only transplanted to the aged mice, the content of dendritic cells in the spleen of the receptor mice can be reduced, differentiation of helper T cells can be inhibited, expression of inflammation-related genes can be remarkably reduced, and the inflammation-related effects can be improved. Further, the immune inflammatory response of the receptor mouse is regulated.

The invention relates to the compound urolithin A and its compositions for topical use in inflammatory skin conditions of various etiologies. Anti-inflammatory activity has been demonstrated in vivo in a model of inflammation of the ear caused by infiltration with dinitrochlorobenzene in rats. Topical application of an ointment containing 0.2 and 1.0% urolithin A resulted in a decrease in ear edema and scratching frequency, which was associated with a decrease in the number of immune cells responsible for the progression of inflammation. The results obtained indicate the possibility of using a composition containing urolithin A in local therapy of skin inflammations, in treatment of which hydrocortisone or other steroids are currently used.

Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.

This invention belongs to the field of regenerative medicine, specifically relating to a lacrimal gland organoid culture medium and a method for in vitro culture of lacrimal gland organoids. In one aspect, a lacrimal gland stem cell proliferation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, and Noggin; the lacrimal gland stem cell basal culture medium comprises: DMEM medium, F12 medium, L-glutamine, fetal bovine serum, hydrocortisone, cholera toxin, B27, penicillin, streptomycin, amphotericin B, and fasudil. In another aspect, a lacrimal gland stem cell differentiation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, Noggin, and BMP7. The lacrimal gland organoids constructed by this invention are larger in volume than those of existing technologies, possessing numerous branched ducts and vesicular acinar structures, extending radially and multidirectionally in a three-dimensional manner, forming a complex and regular three-dimensional tubular acinar network, and possessing secretory function.

The invention provides a method for producing porcine rotavirus based on suspension culture of a PK15 cell reactor, and belongs to the technical field of large-scale preparation of veterinary virus biological products. A Trans VA-06 special culture medium containing functional components such as hydrocortisone, IGF-1 and cholesterol is adopted, a PK15 cell high-density suspension system is constructed in a reactor, harvesting is conducted within 20-36 h when CPE is larger than or equal to 80% by accurately regulating and controlling the initial inoculation density, the culture volume, the stirring rotating speed and the ventilation / oxygen flux and cooperating with a virus inoculation strategy for fixing MOI, and it is shown through multiple batches of results that the PK15 cell high-density suspension system can be obtained. The titer of the obtained virus is stably 9.0 to 10.0 log10 TCID50 / mL, and the repeatability among batches is excellent; according to the method, the large-scale production efficiency and the product quality stability are improved, and the method is suitable for industrial production of the porcine rotavirus vaccine.

Hydrocortisone Pharmaceutical Solution for Injection Device. The invention relates to a hydrocortisone pharmaceutical solution comprising, in mg per 1 mL of solution: - between 150 mg and 170 mg of hydrocortisone or a pharmaceutically acceptable salt thereof in equivalent quantity, - between 2 mg and 7.5 mg of monothioglycerol, - q.s. 1 mL of solvent. The invention also relates to its use in the treatment of acute adrenal insufficiency and asthma. The invention further relates to an injection kit comprising an injection device and this pharmaceutical solution. Figure for the abstract: Fig. 1.